iOmx Therapeutics AG

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

iOmx Therapeutics , a German biopharma company developing cancer therapies based on next generation immune checkpoint targets, has announced the closing of a series B round totaling €65m. Investors ha

Achilles Launches With £13.2m Series A Round Cancer company Achilles Therapeutics Ltd. has launched with a £13.2m ($16.9m) Series A round provided by CRT Pioneer Fund, UCL Technology Fund, and com